RT Journal Article
SR Electronic
T1 High density lipoprotein cholesterol and risk of subsequent COVID-19 hospitalisation: the UK Biobank study
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2021.01.20.21250152
DO 10.1101/2021.01.20.21250152
A1 Camille Lassale
A1 Mark Hamer
A1 Álvaro Hernáez
A1 Catharine R. Gale
A1 G. David Batty
YR 2021
UL http://medrxiv.org/content/early/2021/01/26/2021.01.20.21250152.abstract
AB Introduction While unfavourable changes in High Density Lipoprotein (HDL)-cholesterol appear to be a consequence of COVID-19, the reverse has been little-studied. Our objective was to test whether HDL-cholesterol within the normal range is associated with subsequent COVID-19 hospitalisation.Design We examined 317,306 participants in the prospective UK Biobank study with complete data on HDL-cholesterol and covariates at baseline (2006-2010). Follow-up for COVID-19 status was via hospitalisation records in England (16th March and 31st May 2020). Death certificates for the period 1st March to 30th September 2020 with an underlying cause denoted as COVID-19 (emergency ICD-10 code U07.1) were also utilised.Results Lower COVID-19 hospitalisation risk was apparent in people with higher level of HDL-cholesterol, adjusting for factors including health behaviours, inflammatory markers, and socio-economic status. The association appeared to be linear so that for each 0.2 mmol/L increase in HDL-cholesterol, the odds ratio for COVID-19 hospitalisation was 0.91 (95% confidence interval: 0.86, 0.96). A similar pattern of association was apparent when deaths from COVID-19 was the outcome of interest.Conclusions Adequately high levels of HDL-cholesterol are associated with a lower risk of severe COVID-19.Competing Interest StatementThe authors have declared no competing interest.Funding StatementCL is supported by the Beatriu de Pinos postdoctoral programme of the Government of Catalonia's Secretariat for Universities and Research of the Ministry of Economy and Knowledge (2017-BP-00021); GDB is supported by the Medical Research Council (MR/P023444/1) and the US National Institute on Aging (1R56AG052519-01; 1R01AG052519-01A1); MH through a joint award from the Economic Social Research Council and Medical Research Council (RES-579-47-0001).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Ethical approval was provided by the North-West Multi-centre Research Ethics Committee (11/NW/0382; 16/NW/0274).All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesData sharing: Data from UK Biobank (https://www.ukbiobank.ac.uk/) are available to bona fide researchers on application. Part of this research has been conducted using the UK Biobank Resource under Application 10279. https://www.ukbiobank.ac.uk/